Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium.
Hilary A RobbinsAida Ferreiro-IglesiasTim WaterboerNicole BrennerMari NygårdNoemi BenderLea SchroederAllan HildesheimMichael PawlitaGypsyamber D'SouzaKala VisvanathanHilde LangsethNicolas F SchlechtLesley F TinkerIlir AgalliuSylvia Wassertheil-SmollerEivind Ness-JensenKristian HveemSara GrioniRudolf KaaksMaria-Jose SánchezElisabete WeiderpassGraham G GilesJonathan BeesleyQiuyin CaiWilliam J BlotQuan LongStephanie J WeinsteinDemetrius AlbanesWen-Yi HuangNeal D FreedmanAimée R KreimerMattias J JohanssonPaul J BrennanPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
We estimate that a substantial proportion of HPV16-E6 seropositive individuals will develop OPC, with 10-year risks of 17%-27% for males and 4%-6% for females age 50-60 years in the United States. This high level of risk may warrant periodic, minimally invasive surveillance after a positive HPV16-E6 serology test, particularly for males in high-incidence regions. However, an appropriate clinical protocol for surveillance remains to be established.